What type of study is this?

September 5, 2025In VivoOpen Access

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Recurrent Endometrial Cancer With Peritoneal Carcinomatosis

View Full Paper

Ask AI

Bookmark

Authors

ELEvangelos LolisKyanous Stavros Hospital DKD. Kyziridis AKA. KalakonasKyanous Stavros Hospital

Discussion

Member takes

Implication

Retrospective analysis reveals that cytoreductive surgery and HIPEC enhance survival in patients with peritoneal carcinomatosis, suggesting an effective treatment approach.

Key Points

Cytoreductive surgery combined with HIPEC achieved a 5-year overall survival rate of 78% in patients.
Severe morbidity occurred in 8.68% of patients, with no recorded hospital mortality, indicating a safe treatment protocol.
Complete or near-complete cytoreduction was achieved in 82.6% of cases, highlighting its efficacy.
The completeness of cytoreduction score serves as a significant prognostic variable for survival outcomes.

Cite This Study

Lolis et al. (2025) studied this question.

synapsesocial.com/papers/68bb3edf2b87ece8dc956f61 https://doi.org/10.21873/invivo.14083

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis reveals that cytoreductive surgery and HIPEC enhance survival in patients with peritoneal carcinomatosis, suggesting an effective treatment approach.

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Recurrent Endometrial Cancer With Peritoneal Carcinomatosis

Discussion

Member takes

Implication

Key Points

Cite This Study

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Recurrent Endometrial Cancer With Peritoneal Carcinomatosis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider